-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Cannabinoids in the management of spasticity associated with multiple sclerosis
Review
(2666) Views (479) Full article downloads
Authors: Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco
Published Date August 2008
Volume 2008:4(5) Pages 847 - 853
DOI: http://dx.doi.org/10.2147/NDT.S3208
Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno
Abstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS.
Keywords: cannabinoids, multiple sclerosis, spasticity
Readers of this article also read:
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
Potential cellular and regenerative approaches for the treatment of Parkinson’s disease
Validity and reliability of the Structured Clinical Interview for Depersonalization–Derealization Spectrum (SCI-DER)
Pupillography of automated swinging flashlight test in amblyopia
Attention-deficit-hyperactivity disorder and reward deficiency syndrome
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




